Status:
COMPLETED
Ketotifen: as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy
Lead Sponsor:
Horus University
Conditions:
Breast Cancer
Iron Chelation
Eligibility:
FEMALE
30-60 years
Brief Summary
The objective of our study was to evaluate the expected cardioprotective effects of ketotifen due to its activity as an iron-chelating agent previously uncovered by us in the in vitro chemical test wh...
Detailed Description
The objective of our study was to evaluate the expected cardioprotective effects of ketotifen due to its activity as an iron-chelating agent previously uncovered by us in the in vitro chemical test wh...
Eligibility Criteria
Inclusion
- cancer patients receiving anthracycline chemotherapy in their protocol alone (without any cardioprotective agent),
- aged 30-60, and
- female subjects were included as they were female breast cancer patients, and,
- patients who had an adequate baseline echocardiography.
Exclusion
- who had a history of heart failure,
- arrhythmia,
- cardiac catheterizations,
- angina,
- uncontrolled hypertension, and
- uncontrolled diabetes,
- patients with impaired liver function tests,
- patients who previously received anthracycline-containing regimens, and
- any cardiotoxic chemotherapy regimens, previous history of chest wall irradiation.
- Brian metastasis.
Key Trial Info
Start Date :
January 14 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 13 2019
Estimated Enrollment :
111 Patients enrolled
Trial Details
Trial ID
NCT04435028
Start Date
January 14 2019
End Date
August 13 2019
Last Update
June 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Horus University
Damietta, Damiete Governonate, Egypt, 12345